



The company reported a strong Q3 FY26 performance with revenue growth of 27% YoY, while EBITDA and PAT grew 45% and 48% YoY respectively, reflecting operating leverage benefits driven by Healthcare scale-up. Margin expansion remains the key highlight, supported by favorable product mix and improving execution in GLP-1 programs.

The outlook for FY26 remains very strong.

Key business highlights for Q3FY26

- Two new GLP-1 customers onboarded during the quarter, along with signing of two new global pharma pen programs, enhancing medium-term volume visibility.
- Leadership strengthening: Appointment of a new CEO (Ex-SHL) to drive the next phase of global scale-up, operational excellence and strategic execution.

Outlook

- Healthcare expected to sustain 30–40% growth over the next few years driven by GLP-1 platform scale-up and new device launches
- Abu Dhabi facility (75 mn units) provides long-term scalability with 50–60% capacity already secured via take-or-pay arrangements.
- Consumer segment expected to gradually stabilize, while Healthcare mix continues to structurally improve consolidated margins.

Financial Summary

Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
Net sales	6,071	6,439	7,868	10,464	13,055	16,698
Growth	6.9%	6.1%	22.2%	33.0%	24.8%	27.9%
EBIDTA	919	1,169	1,761	3,008	4,033	5,108
Growth	13.2%	27.3%	50.6%	70.9%	34.0%	26.7%
Margins (%)	15.1%	18.2%	22.4%	28.7%	30.9%	30.6%
Adjusted net profit	352	573	931	1,846	2,594	3,382
Growth	-0.3%	63.0%	62.6%	98.2%	40.5%	30.4%
EPS (Rs)	7.7	12.5	20.3	40.2	56.6	73.7
P/E (x)	222	158	97	49	35	27
EV/EBITDA (x)	87	79	52	30	22	17
RoCE (%)	9.96%	12.17%	18.21%	29.13%	31.56%	31.52%
RoE (%)	8.76%	12.48%	17.01%	25.37%	26.40%	25.70%


Source: Dalal & Broacha

Rating	TP (Rs)	Up/Dn (%)
BUY	2,802	40

Market Data

Current price	Rs	2,004
Market Cap (Rs.Bn)	(Rs Bn)	92
Market Cap (US\$ Mn)	(US\$ Mn)	1,016
Face Value	Rs	2
52 Weeks High/Low	Rs	799.9 / 1304.65
Average Daily Volume	('000)	197
BSE Code		501423
Bloomberg		SHEP.IN
Source: Bloomberg		

One Year Performance



% Shareholding	Dec-25	Sep-25
Promoters	43.40	43.72
Public	56.60	56.28
Total	100.00	100.00

Source: BSE

Het Shah

+91 22 67141414

het.shah@dalal-broacha.com

Financial Highlights

➤ Q3 FY26 Highlights:

- Revenue stood at ₹251 cr (+27% YoY), led by strong Healthcare traction.
- EBITDA came in at ₹66 cr (+45% YoY); margin expanded to 26.5% (+327 bps YoY).
- PAT reported at ₹37 cr (+48% YoY); PAT margin improved to 14.9% (+220 bps YoY).

➤ 9M FY26 Highlights:

- Revenue at ₹754 cr (+32% YoY) indicating sustained growth momentum.
- EBITDA of ₹218 cr (+76% YoY); margin at 29% (+720 bps YoY).
- PAT at ₹130 cr (+101% YoY) supported by strong mix-led expansion.
- Cash PAT at ₹166 cr (+73% YoY), reflecting healthy cash generation.

Concall KTA's

➤ Healthcare Vertical - Structural Shift Toward Healthcare

- Revenue: ₹1043 Mn (+139% YoY) | Contribution: ~42% of overall sales
- GLP-1 commercial supplies now active across Canada, Brazil, India, Middle East and Turkey, indicating successful execution beyond pilot scale.
- ~65–75% market share among early semaglutide filers in Canada reflects strong positioning in first-wave generics.
- FY26 volume guidance maintained at ~30 mn pens (minor moderation due to 3-month timing delay, not demand-related).
- Pricing erosion of 10–15% on large contracts acknowledged; management expects stabilization over ~24 months as competition normalizes.
- Two new GLP-1 customers on boarded during the quarter; two additional global pharma pen programs signed, strengthening forward pipeline.


➤ Consumer Vertical

- Revenue: ₹1,228 Mn (–13% YoY)
- Decline due to continued slowdown in Europe and US discretionary demand
- Consumer margins remain stable; mix dilution impact offset by healthcare outperformance.
- Consumer Electronics entry (high-precision small parts) under qualification
- Electronics expected to carry better margin profile versus traditional home furnishing products.


➤ Industrial Vertical

- Revenue: ₹234 Mn (+87% YoY)
- Semiconductor casing opportunity progressing — engaged with all four upcoming Indian fabs.


Focus Charts

Capacity utilisation on a increasing trajectory
(based on man hours)


Polymers processed on a growth trajectory



Strong growth in Healthcare (excl UK Rs Mn)



Strong growth in Healthcare (UK Rs Mn)



Source: Company, Dalal & Broacha Research

Valuation and Outlook:

At CMP of Rs 2,006 the company is trading at 50x/35x/27x FY26E/FY27E/FY28E. We have not baked in any revenue from consumer electronics in our estimates as there is lack of clarity.

We have revised our EPS estimates by +2%/-7%/-1% in FY26/FY27/FY28 based on how Q3 has panned out.

We value the company at 38x FY28E and arrive at a target price of Rs. 2,802.

Quarterly Snapshot

	YoY				
Particulars (Rs Mns)	Q3FY26	Q3FY25	Growth	Q2FY26 QoQ	Growth
Revenue from operations	2,505	1,976	26.8%	2,567	-2.4%
Other income	1	4	-83.9%	23	-96.9%
Total Income	2,506	1,980		2,589	
COGS	1,041	1,037	0.4%	1,045	-0.3%
Employee Benefit expenses	282	196	44.0%	263	7.3%
Other Expenses	438	206	112.4%	377	15.9%
Power and Fuel	80	78	2.8%	88	-8.5%
EBITDA (excl other income)	663	459	44.6%	793	-16.4%
Less : Depreciation	125	107	17.4%	120	4.3%
PBIT	538	352		673	
Less: Interest cost	44	41	5.8%	39	11.9%
PBT (before exceptional)	495	315	57.1%	657	-24.6%
Exceptional	-	-		-	
PBT (after exceptional)	495	315	57.1%	657	-24.6%
Less : Tax	121	63		145	
PAT	374	252	48.4%	512	-27.0%
EPS	8.13	5.49	48.1%	11.17	-27.2%
Gross Margins	58.42%	47.52%		59.28%	
EBITDA Margins	26.48%	23.21%		30.91%	
Net profit Margin	14.92%	12.72%		19.79%	

* Consolidated P/L

Source: Company, Dalal & Broacha Research

FINANCIALS

P&L (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Net Sales	6,439	7,868	10,464	13,055	16,698
Total Operating Expenses	3,701	4,158	4,615	5,875	7,681
Employee Cost	573	804	1,070	1,338	1,605
Power and Fuel	292	315	345	457	584
Other Expenses	703	830	1,426	1,353	1,720
Operating Profit	1,169	1,761	3,008	4,033	5,108
Depreciation	357	421	459	498	526
PBIT	813	1,339	2,550	3,535	4,582
Other income	65	23	51	55	59
Interest	179	169	140	132	132
PBT (Before exceptional)	698	1,193	2,461	3,459	4,510
PBT (post exceptional)	698	1,193	2,461	3,459	4,510
Provision for tax	126	262	615	865	1,127
Reported PAT	573	931	1,846	2,594	3,382

Balance Sheet (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Equity capital	92	92	92	92	92
Reserves	4,500	5,385	7,185	9,733	13,069
Net worth	4,592	5,477	7,277	9,825	13,161
Non Current Liabilities	941	678	482	389	394
Current Liabilities	2,292	3,171	3,358	3,888	4,376
TOTAL LIABILITIES	7,825	9,326	11,117	14,101	17,931
Non Current Assets	5,153	5,470	5,926	5,965	5,978
Tangible + Intangible Assets	4,938	5,189	5,631	5,644	5,628
Non Current Investments	0	0	-	-	-
Income Tax Asset	27	38	27	27	27
Other Financial Assets	5	5	5	5	5
Other Non Current Assets	183	239	263	289	318
Current Assets	2,672	3,856	5,191	8,136	11,954
Inventories	836	1,378	1,577	1,967	2,516
Trade Receivables	1,174	1,717	2,150	2,683	2,974
Cash and Bank Balances	264	231	856	2,788	5,662
Short Term Loans and Advances	64	3	3	3	3
Other Current Assets	335	526	605	695	799
TOTAL ASSETS	7,825	9,326	11,117	14,101	17,931

FINANCIALS

Cash flow statement (Rs in mn)	FY24	FY25	FY26E	FY27E	FY28E
Cash flow from operating activities					
Profit before tax	698	1,193	2,461	3,459	4,510
Depreciation & Amortization	357	421	459	498	526
Interest expenses	179	169	140	132	132
Operating profit before working capital change	1,234	1,784	3,059	4,088	5,167
Working capital adjustment	(208)	(781)	(332)	(603)	(620)
Gross cash generated from operations	1,026	1,002	2,727	3,484	4,548
Direct taxes paid	(88)	(262)	(615)	(865)	(1,127)
Others	(16)	323	(1)	98	141
Cash generated from operations	923	1,064	2,111	2,718	3,561
Cash flow from investing activities					
Capex	(950)	(672)	(901)	(510)	(510)
Others					
Cash generated from investment activities	(938)	(672)	(901)	(510)	(510)
Cash flow from financing activities					
Proceeds from issue of share	-	-	-	-	-
Share premium received on issue of shares	-	-	-	-	-
Borrowings/ (Repayments)	210	(208)	(400)	(97)	-
Interest paid	(159)	(169)	(140)	(132)	(132)
Dividend paid	-	(46)	(46)	(46)	(46)
Others	(5)	-		-	-
Cash generated from financing activities	46	(424)	(585)	(275)	(177)
Net cash increase/ (decrease)	31	(32)	624	1,933	2,873

Ratios	FY24	FY25	FY26E	FY27E	FY28E
OPM	18.2%	22.4%	28.7%	30.9%	30.6%
NPM	8.8%	11.8%	17.6%	19.8%	20.2%
Tax Rate	18.0%	21.9%	25.0%	25.0%	25.0%
Growth Ratios (%)					
Net Sales	6.1%	22.2%	33.0%	24.8%	27.9%
Operating Profit	27.3%	50.6%	70.9%	34.0%	26.7%
PBIT	38.7%	64.8%	90.4%	38.6%	29.6%
PAT	63.0%	62.6%	98.2%	40.5%	30.4%
Per Share (Rs.)					
Net Earnings (EPS)	12.5	20.3	40.2	56.6	73.7
Dividend	1.0	1.0	1.0	1.0	1.0
Book Value	100.1	119.4	158.6	214.2	286.9
Free Cash Flow	-0.3	4.3	13.2	24.1	33.3
Valuation Ratios					
P/E(x)	158.1	97.3	49.1	34.9	26.8
P/B(x)	19.7	16.5	12.4	9.2	6.9
EV/EBIDTA(x)	79.0	52.4	30.3	22.1	16.9
Div. Yield(%)	0.1	0.1	0.1	0.1	0.1
FCFF Yield(%)	0.0	0.2	0.7	1.2	1.7
Return Ratios (%)					
ROE	12.5%	17.0%	25.4%	26.4%	25.7%
ROCE	12.2%	18.2%	29.1%	31.6%	31.5%
ROIC	10.4%	14.7%	24.2%	31.5%	38.7%

Source: Company, Dalal & Broacha Research

Disclaimer

Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D&B (CINU67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided

herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021.
Tel: 91-22- 2282 2992, 2287 6173 | E-mail: equity.research@dalal-broacha.com